ArticleOncotarget2021
Circulating low density neutrophils of breast cancer patients are associated with their worse prognosis due to the impairment of T cell responses.
Article in Oncotarget, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- Human immunosuppressive neutrophils: recent answers to old and new questions.The EMBO journal · 2026Review
- Article
- Fatty acids in the tumor microenvironment reprogram neutrophils to induce immunosuppression via adenosine.bioRxiv : the preprint server for biology · 2026Article
- Advances in the study of low-density neutrophils in rheumatic diseases.Frontiers in immunology · 2026Review
- Prognostic Value of the Advanced Lung Cancer Inflammation Index for Predicting in-Hospital Mortality in Intensive Care Unit Patients with Septic Shock: A Retrospective Cohort Study.Journal of inflammation research · 2026Article
- Metabolic Control of Immunity-Unveiling Neutrophil Mechanisms.Advances in experimental medicine and biology · 2026Review
- Neutrophils matter: new clinical insights on their role in the progression of metastatic breast cancer.Breast cancer research : BCR · 2025Article
- Therapeutic potential of tumor-associated neutrophils: dual role and phenotypic plasticity.Signal transduction and targeted therapy · 2025Review
- The balance between N1 and N2 neutrophils implications for breast cancer immunotherapy: a narrative review.Annals of medicine and surgery (2012) · 2025Review
- Neutrophils as key regulators of tumor microenvironment in breast cancer: a focus on N1 and N2 polarization.Annals of medicine and surgery (2012) · 2025Review
- Circulating Tumor Microenvironment in Metastasis.Cancer research · 2025Review
- Interaction of low-density neutrophils with other immune cells in the mechanism of inflammation.Molecular medicine (Cambridge, Mass.) · 2025Review
- Immune suppressive activities of low-density neutrophils in sepsis and potential use as a novel biomarker of sepsis-induced immune suppression.Scientific reports · 2025Article
- Harnessing myeloid cells in cancer.Molecular cancer · 2025Review
- Mechanistic roles of neutrophil heterogeneity in tumour pathogenesis.Frontiers in immunology · 2025Review
- Tumor-associated neutrophils in breast cancer: an angel or a devil?Frontiers in immunology · 2025Review
- Interferon-α Inhibits NET Formation in Neutrophils Derived from Patients with Myeloproliferative Neoplasms in a Neutrophil Sub-Population-Specific Manner.International journal of molecular sciences · 2024Article
- Article
- Review
- Neutrophils in Cancer and Potential Therapeutic Strategies Using Neutrophil-Derived Exosomes.Vaccines · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neutrophils are prominent immune components of tumors, having either anti-tumor (N1) or pro-tumor activity (N2). Circulating neutrophils, divided into high density neutrophils (HDN) and low density neutrophils (LDN), functionally mirror those N1 and N2 cells, respectively. LDN are rare in non-pathological conditions, but frequent in cancer, exhibiting a pro-tumor phenotype. These findings have been mainly demonstrated in animal models, thus proper validation in humans is still imperative. Here, we observed that LDN were increased in the blood of breast cancer (BC) patients, particularly with metastatic disease. Within the population of non-metastatic patients, LDN were more prevalent in patients with poor response to neoadjuvant chemotherapy than patients with a good response. The higher incidence of LDN in BC patients with severe disease or resistance to treatment can be explained by their pro-tumor/immunosuppressive characteristics. Moreover, the percentage of LDN in BC patients' blood was negatively correlated with activated cytotoxic T lymphocytes and positively correlated with immunosuppressive regulatory T cells. The ability of LDN to spoil anti-tumor immune responses was further demonstrated
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.